Short answer
Vera Therapeutics, Inc. (VERA) filed an 8-K current report with the SEC on July 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). William Turner transitions from Chief Regulatory Officer to Special Advisor for Regulatory Affairs effective August 3, 2026.
Vera Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- William Turner transitions from Chief Regulatory Officer to Special Advisor for Regulatory Affairs effective August 3, 2026
- Nancy Bowman, M.D., Ph.D. succeeds Turner as Chief Regulatory Officer on August 3, 2026
- Regulatory leadership change may affect oversight of Vera’s clinical and approval strategy during the transition
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vera Therapeutics, Inc. 8-K filings
Get the next VERA 8-K as it lands
Follow VERA for push alerts, or ask the research agent what this filing means.